Market research
HBP.F Helix BioPharma Corp
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.67
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.67
About
About Helix BioPharma Corp
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HBP.F discussion.
5 years, 5 months ago
Helix BioPharma Corp is currently in a long term uptrend where the price is trading 36.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Helix BioPharma Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 11.7% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 37.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Helix BioPharma Corp gets an overall score of 2/5.